ImmunityBio
IBRX
85 hedge funds and large institutions have $129M invested in ImmunityBio in 2020 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 10 closing their positions.
633% more capital invested
Capital invested by funds: $17.6M → $129M (+$111M)
360% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 10
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
73% more funds holding
Funds holding: 49 → 85 (+36)
3.71% more ownership
Funds ownership: 6.19% → 9.9% (+3.7%)
20% less call options, than puts
Call options by funds: $5.27M | Put options by funds: $6.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.77M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$4.45M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.88M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.82M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$9.36M |
| 2 |
Millennium Management
New York
|
-$873K |
| 3 |
Goldman Sachs
New York
|
-$232K |
| 4 |
HKAM
Horizon Kinetics Asset Management
New York
|
-$170K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$128K |
IBRX Hedge Fund Activity: Q2 2020 in Review
85 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2020, worth a combined $129M — up 633% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IBRX positions and 10 closed out — a net gain of 36 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $7.77M. The largest seller was Renaissance Technologies, cutting an estimated $9.36M.
- 85 institutional investors held ImmunityBio (IBRX) as of Q2 2020, up from 49 in Q1 2020.
- Funds reported $129M of ImmunityBio stock for Q2 2020, up 633% quarter-over-quarter.
- 46 funds opened new ImmunityBio positions in Q2 2020 and 10 closed out, a net change of +36 holders.
- The largest ImmunityBio buyer in Q2 2020 was BlackRock, an estimated $7.77M added.
- The largest ImmunityBio seller in Q2 2020 was Renaissance Technologies, an estimated $9.36M sold.
Based on aggregated 13F filings for Q2 2020.